<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105719">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675362</url>
  </required_header>
  <id_info>
    <org_study_id>4228</org_study_id>
    <nct_id>NCT01675362</nct_id>
  </id_info>
  <brief_title>Renal Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shock Wave Lithotripsy Induced Renal Injury</brief_title>
  <acronym>SWL</acronym>
  <official_title>A Randomized Controlled Trial for Evaluating Renal Protective Effects of Antioxidants (Selenium and Vitamins A, C and E), Calcium Channel Blocker (Verapamil) and Angiotensin Receptor Blocker (Losartan) Against Extracorporeal Shock Wave Lithotripsy Induced Renal Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <authority>Egypt: Science and Technological Development Fund</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the protective effects and mechanisms of
      antioxidants (vitamins A, C, E and Selenium), calcium channel blocker (Verapamil) and
      angiotensin receptor blocker (Lozartan) against shock wave induced renal injuries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protective effect will be evaluated via estimation of the changes in renal tubular
      enzyme (NGAL) and detection of albumen levels in urine. The mechanisms of protection will be
      investigated by estimation of renal perfusion and functional changes using dynamic MRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Renal damage</measure>
    <time_frame>two hours and one week after Extracorporeal shock wave lithotripsy (ESWL)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The protective effect will be evaluated via estimation of the changes in renal tubular enzyme (NGAL) and detection of albumen levels in urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mechanisms of renal protection</measure>
    <time_frame>Before ESWL, 2 hours and 1 week after ESWL</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The mechanisms of protection will be investigated by estimation of renal perfusion and functional changes using dynamic MRI</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Lithotripsy</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>They will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antioxidant group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium channel Blockers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiotensin receptor blocker group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antioxidant group</intervention_name>
    <description>They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week</description>
    <arm_group_label>Antioxidant group</arm_group_label>
    <other_name>Selenium ACE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Channel Blockers</intervention_name>
    <description>They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week</description>
    <arm_group_label>Calcium channel Blockers</arm_group_label>
    <other_name>Verapamil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin receptor blocker group</intervention_name>
    <description>They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week</description>
    <arm_group_label>Angiotensin receptor blocker group</arm_group_label>
    <other_name>Losartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>They will receive placebo</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Well functioning kidney (serum creatinine &lt;1.2 mg/dl).

          2. Solitary renal stone.

          3. Size: 25 mm or less in the largest diameter.

        Exclusion Criteria:

          1. Contraindications to ESWL

          2. Previous surgical treatment of renal stones.

          3. Congenital renal anomalies.

          4. Pediatric patients (age &lt;15 years).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed R. EL-Nahas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khaled Z. Sheir, MD</last_name>
    <phone>0020502262222</phone>
    <phone_ext>1623</phone_ext>
    <email>kzsheir@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed R. EL-Nahas, MD</last_name>
    <phone>00201221136899</phone>
    <email>ar_el_nahas@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansoura</city>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ahmed M. Elshal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed R. EL-Nahas</investigator_full_name>
    <investigator_title>Assistant Professor of Urology</investigator_title>
  </responsible_party>
  <keyword>Extracorporeal shock wave lithotripsy (ESWL)</keyword>
  <keyword>Kidney calculi</keyword>
  <keyword>Renal protection</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>Calcium channel blockers</keyword>
  <keyword>Angiotensin receptor blockers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Selenium</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
